Prudential Financial Inc. Has $6.90 Million Position in Aerie Pharmaceuticals Inc (AERI)

Prudential Financial Inc. boosted its holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 134.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 112,101 shares of the company’s stock after buying an additional 64,360 shares during the period. Prudential Financial Inc. owned approximately 0.25% of Aerie Pharmaceuticals worth $6,900,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Aerie Pharmaceuticals by 9.0% in the second quarter. BlackRock Inc. now owns 2,991,101 shares of the company’s stock valued at $202,049,000 after buying an additional 246,686 shares during the period. FMR LLC lifted its holdings in Aerie Pharmaceuticals by 25.4% in the second quarter. FMR LLC now owns 1,095,652 shares of the company’s stock valued at $74,011,000 after buying an additional 221,582 shares during the period. Columbus Circle Investors lifted its holdings in Aerie Pharmaceuticals by 3.1% in the third quarter. Columbus Circle Investors now owns 798,376 shares of the company’s stock valued at $49,140,000 after buying an additional 24,196 shares during the period. Bank of New York Mellon Corp lifted its holdings in Aerie Pharmaceuticals by 5.5% in the second quarter. Bank of New York Mellon Corp now owns 630,612 shares of the company’s stock valued at $42,597,000 after buying an additional 32,820 shares during the period. Finally, Frontier Capital Management Co. LLC lifted its holdings in Aerie Pharmaceuticals by 51.4% in the third quarter. Frontier Capital Management Co. LLC now owns 553,245 shares of the company’s stock valued at $34,052,000 after buying an additional 187,810 shares during the period.

AERI opened at $39.69 on Friday. Aerie Pharmaceuticals Inc has a twelve month low of $38.50 and a twelve month high of $74.75.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, November 6th. The company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.33) by ($0.40). The business had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.63 million. Research analysts forecast that Aerie Pharmaceuticals Inc will post -5.48 EPS for the current year.

In related news, Director Gerald D. Cagle acquired 2,000 shares of the stock in a transaction dated Friday, November 16th. The stock was bought at an average price of $41.75 per share, with a total value of $83,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $60.56, for a total transaction of $666,160.00. Following the sale, the insider now directly owns 138,187 shares of the company’s stock, valued at approximately $8,368,604.72. The disclosure for this sale can be found here. Insiders have sold 134,117 shares of company stock valued at $7,784,846 in the last three months. 10.53% of the stock is owned by insiders.

Several research firms have weighed in on AERI. Cantor Fitzgerald reiterated a “buy” rating and issued a $86.00 target price on shares of Aerie Pharmaceuticals in a report on Tuesday, October 2nd. Cowen set a $105.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 6th. BidaskClub lowered shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, September 1st. Mizuho reiterated a “buy” rating and issued a $77.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday, November 7th. Finally, Stifel Nicolaus increased their target price on shares of Aerie Pharmaceuticals from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Tuesday, September 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $79.25.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/prudential-financial-inc-has-6-90-million-position-in-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: What is the LIBOR?

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply